Chinese medicament for treating benign prostatic hyperplasia

Abstract

The invention discloses a Chinese medicament for treating benign prostatic hyperplasia, which comprises the following components in part by weight: 1 to 10 parts of panax ginseng, 1 to 10 parts of astragalus, 1 to 10 parts of notoginseng root, 1 to 10 parts of cinnamomvine, 1 to 10 parts of oriental waterplantain rhizome, 1 to 10 parts of south dodder seed, 1 to 10 parts of sharpleaf galangal fruit, 1 to 10 parts of peach seed, 1 to 10 parts of Chinese thorowax root, 1 to 10 parts of largetrifoliolious bugbane rhizome, 1 to 10 parts of liquoric root and 1 to 10 parts of ricepaperplant pith. The Chinese medicament has the effects on middle-jiao regulation, kidney reinforcement, discharge and retention of body fluid and abdominal mass elimination, has the main effects of tonifying the kidney and consolidating the constitution, controlling salivation, elevating yang qi, eliminating abdominal mass and inducing diuresis, ascending lucid yang, descending turbid yin, opening and closing in order and prolonging the longevity, and is suitable for curers who need operation or patients who cannot perform operation due to health or other reasons in middle and old-aged men who suffer from frequent micturition, urgent urination, small urinary stream, acraturesis, urinary dribbling, urinary hesitancy, urinary incontinence and urine retention which are caused by benign prostatic hyperplasia and hypertrophy.

Description

technical field [0001] The invention relates to a traditional Chinese medicine for treating benign prostatic hyperplasia. Background technique [0002] Prostatic hyperplasia, also known as prostatic hypertrophy, is a common disease of middle-aged and elderly men. It is also known as benign prostatic hypertrophy. The hyperplasia gland is located in the bladder neck, which obstructs the urinary tract, causing frequent urination and difficulty urinating. Urine, as the glands grow larger, gradually exceeds the compensatory capacity of the bladder, and the urine remains in the bladder, and symptoms aggravate, and even urinary retention or upper urinary tract hydrops occur. At present, the commonly used treatment methods include physical VCD therapy, surgical treatment and drug therapy. Surgical treatment will cause great trauma to the patient due to premature delivery, and cannot be used as a conventional method for the treatment of benign prostatic hyperplasia; physical VCD ther...

AI Technical Summary

Problems solved by technology

At present, the commonly used treatment methods include physical VCD therapy, surgical treatment and drug therapy. Surgical treatment will cause great trauma to the patient due to premature delivery, and cannot be used as a conventional method for the treatment of benign prostatic hyperplasia; physical VCD therapy uses high-frequency far-infrared electromagnetic and other functional functions Force the prostate tube to open and drain, and excrete the pathogenic microorganisms and metabolites in the prostate along the urethra, so as to improve and promote the blood circulation of the prostate and reduce the pressure of the prostate congestion. However, the treatment cycle of this method is long, and this method is mainly for the treatment of prostate For prostatic hyperplasia, it only has a relieving effect, and cannot fundamentally eliminate the hyperplastic prostate tissue; existing drug treatments are divided into traditional Chinese medicine and western medicine, but they all have the disadvantages of long treatment cycle and easy recurrence, and the treatment effect is not good. Ideal, but western medicine treatment still has the problem of relatively large side effects